Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 5/20 | 0.54 |
| ▸ | PAK3 | O75914 | 1/20 | 0.54 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 3/20 | 0.51 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 4/20 | 0.47 |
| ▸ | CCNK | O75909 | 1/20 | 0.44 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24065156 | 0.91 | IGF1R (0.50) | PAK1PAK3PAK2IGF1RNEK1 | |
| SCHEMBL28664529 | 0.91 | IGF1R (0.50) | PAK1PAK3PAK2IGF1RNEK1 | |
| SCHEMBL24065121 | 0.88 | IGF1R (0.51) | PAK1IGF1RNEK1NTRK1PAK4 | |
| SCHEMBL14723558 | 0.86 | PAK1 (0.52) | PAK1PAK3PAK2IGF1RNEK1 | |
| SCHEMBL1164508 | 0.86 | IGF1R (0.65) | PAK1IGF1RNEK1NTRK1PAK4 | |
| SCHEMBL14723204 | 0.84 | IGF1R (0.60) | PAK1IGF1RNEK1PAK4 | |
| SCHEMBL14723540 | 0.84 | IGF1R (0.60) | PAK1PAK3PAK2IGF1RNEK1 | |
| SCHEMBL15091442 | 0.80 | PAK1 (0.52) | PAK1PAK3PAK2IGF1RNEK1 | |
| SCHEMBL15091647 | 0.80 | PAK1 (0.52) | PAK1PAK3PAK2IGF1RNEK1 | |
| SCHEMBL15091653 | 0.80 | PAK1 (0.52) | PAK1PAK3PAK2IGF1RNEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024206628-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2024-10-03 | — | — | WO | disclosed |
| EP-3927699-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | Nalo Therapeutics (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20210369710-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2021-12-02 | — | — | US | disclosed |
| CN-113710663-A | Modulators of MYC family proto-oncogene proteins | 纳罗医疗公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-2794605-A1 | 2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-8815877-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2748159-A1 | SERINE/THREONINE PAK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013092940-A1 | 2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, PAK3 | PAK1 1/4885PAK3 3/4885PAK2 14/4885 |
| US-20210369710-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | PAK1 222/4885PAK3 447/4885PAK2 446/4885 |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | PAK1 1/4885PAK3 6/4885PAK2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.